两种方案治疗56例宫颈癌骨转移的回顾性分析

发布时间：2018-09-12 16:45

【摘要】：目的:评价两种方案治疗宫颈癌骨转移患者的疗效及毒副反应。方法:回顾性收集资料完整的宫颈癌骨转移患者56例,按治疗方案分为放化疗组(31例)和双膦酸盐组(25例),放化疗组患者采用放、化疗联合双膦酸盐治疗,双膦酸盐组采取双膦酸盐姑息对症治疗,3~4周为1个疗程,两组患者均治疗3个疗程。比较两组患者平均生存时间、生存质量及毒副反应。结果:宫颈癌骨转移后放化疗组患者平均生存时间为17月(95%CI:9.1~24.9),双膦酸盐组为19月(95%CI:2.4~35.6);3年生存率放化疗组患者为16.1%,双膦酸盐组为16.0%,组间比较差异均无统计学意义(P=0.820)。3个疗程后患者KPS评分比较,放化疗组患者改善率(22.6%)明显低于双膦酸盐组(40.0%),差异有统计学意义(χ2=4.36,P0.05);放化疗组毒副作用较双膦酸盐组明显。结论:双膦酸盐对患者生存质量影响较小,毒副反应不明显,临床上值得推荐给部分晚期、高龄、复发的宫颈癌转移患者。
[Abstract]:Objective: to evaluate the efficacy and toxicity of two regimens in the treatment of cervical cancer with bone metastasis. Methods: a total of 56 patients with bone metastasis from cervical cancer were retrospectively collected and divided into radiotherapy and chemotherapy group (31 cases) and bisphosphonate group (25 cases). The patients in the radiotherapy and chemotherapy group were treated with radiotherapy and chemotherapy combined with bisphosphonate. Bisphosphonate group was treated by palliative treatment with bisphosphonate for 3 weeks as a course of treatment, and the two groups were treated for 3 courses. The mean survival time, quality of life and toxicity were compared between the two groups. Results: the mean survival time was 17 months (95%CI:9.1~24.9) and 19 months (95%CI:2.4~35.6) in the radiotherapy and chemotherapy group after bone metastasis, while the survival rate was 16. 1 in the radiotherapy and chemotherapy group and 16. 0 in the bisphosphonate group. There was no significant difference among the three groups (P0. 820). Comparison of KPS scores of patients after course, The improvement rate of radiotherapy and chemotherapy group (22.6%) was significantly lower than that of bisphosphonate group (40.0%), the difference was statistically significant (蠂 2 / 4.36 P 0.05), and the side effect of radiotherapy and chemotherapy group was more obvious than that of bisphosphonate group. Conclusion: bisphosphonates have little effect on the quality of life and have no obvious side effects. It is recommended to some advanced, advanced and recurrent cervical cancer metastasis patients clinically.
【作者单位】：重庆市肿瘤研究所;
【分类号】：R737.33

【共引文献】